RxDoctor Payments DataLook up a doctor →

Craig Neitzel, MD

Dermatology · Champaign, ILNPI 1275640617

Payments from drug & device makers

$320,917in general payments, 2019–2025

Across 1,073 payments — averaging $299.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$151K
  • Amgen$56K
  • UCB, Inc.$30K
  • Bristol Myers Squibb$18K
  • Dermavant Sciences, Inc.$14K
  • Galderma Laboratories, L.p.$13K
  • plus $38K from 25 others

What the payments were for

  • Consulting fees$12,1734%
  • Speaking & faculty fees$274,07685%
  • Travel & lodging$14,7805%
  • Food & beverage$18,9416%
  • Education$9470%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$320,917 in reported general payments places this provider in the 95th percentile of 606 dermatology providers in Illinois.

See all dermatology providers in Illinois

Medicare billing

Part B allowed, 2024
$282,203
Medicare patients
893
Services billed
6,797

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept26$209,038
OtezlaApremilast21$146,901
Humira(Cf) PenAdalimumab15$135,454
Dupixent PenDupilumab32$130,927
Dupixent SyringeDupilumab26$95,675
Taltz SyringeIxekizumab11$74,852
Amjevita(Cf) AutoinjectorAdalimumab-Atto12$38,130
Tacrolimus97$18,204
EucrisaCrisaborole12$13,773
Pimecrolimus30$12,247
Clobetasol Propionate234$10,144
Acitretin15$6,472
Ivermectin16$5,939
Metronidazole136$5,370
Triamcinolone Acetonide343$5,064

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$55,998$146,90121 claims
PfizerEucrisa$732$13,77312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 606 dermatology providers in Illinois.

Other dermatology in Champaign

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →